Sortase-Mediated Insulin Derivative Synthesis via LPXT Motif
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The current insulin glulisine manufacturing process is costly and complex, requiring 15 steps and involving multiple facilities, while existing methods for insulin derivatives like glargine are limited by the need for specific Arginine residues at the B-chain end, restricting their application to long-acting insulins.
Innovation Solution
A method is developed to genetically modify yeast or bacteria to express sortase from Staphylococcus aureus and a single chain peptide with the Leucine-Proline-X-Threonine motif, allowing for simplified synthesis of insulin derivatives with reduced catalyst expenditure and enabling production at a single facility, by modifying vectors like pPIC9K and pGAPZα to enhance transformant expression and cleavage efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the current insulin glulisine manufacturing process is used, then insulin derivative production is achieved, but the process is costly and complex requiring 15 steps and multiple facilities
Solution Approach 1:
The patent combines multiple separate manufacturing operations into a single integrated system. The sortase enzyme and LPXT motif are integrated into the insulin derivative structure, allowing the cleavage and release steps to occur automatically during the expression process itself, eliminating the need for separate downstream processing facilities and reducing the total number of manufacturing steps from 15 to a simplified multi-step process.
Solution Approach 2:
The sortase recognition motif (LPXT) is built into the insulin derivative sequence during the initial gene construction phase. This preliminary incorporation of the cleavage site allows the sortase enzyme to automatically perform the release function during normal expression, eliminating the need for subsequent enzymatic conversion steps that would otherwise be required.
2Adaptability or versatility
If existing methods for insulin derivatives like glargine are used, then long-acting insulin production is achieved, but the method is limited by the need for specific Arginine residues at the B-chain end
Solution Approach 1:
The sortase-based system provides a universal solution that works for all insulin derivatives regardless of their specific amino acid sequence requirements. Unlike previous methods that required specific Arginine residues at the B-chain end, the LPXT motif can be incorporated into any insulin derivative structure, making the method applicable to both long-acting and fast-acting insulins and enabling rapid prototyping of new derivatives.
3Ease of manufacture
If the novel sortase method is used, then downstream processing is eliminated and production can be performed at a single facility, but genetic modification of yeast or bacteria is required
Solution Approach 1:
The system is designed so that the host organism (yeast or bacteria) expresses both the insulin derivative precursor with the LPXT motif and the sortase enzyme simultaneously. The sortase enzyme then automatically cleaves the precursor and releases the active insulin derivative during the expression process itself, making the system self-sufficient and eliminating the need for separate downstream processing steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach simplifies the insulin derivative synthesis process, reduces costs, and enables rapid prototyping of new derivatives with similar properties to commercially available insulins, allowing for efficient production of cost-effective insulin derivatives that can be administered subcutaneously.
Implementation Method 1
The novel use of sortase from Staphylococcus aureus eliminates the need for downstream processing
Data Source
AI summary
The present invention relates to insulin derivatives which, in comparison to insulin glulisine and similar derivatives, has a simplified process for synthesis. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which the motif Leucine-Proline-X-Threonine appears at the end of the B-chain, where X is any amino acid residue. Due to the nature of the process, the A-chain and B-chain must begin with a Glycine amino acid residue.